13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2955 trials found

diseases per page:

Showing 1 to 10 of 2,955 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05179577 (ClinicalTrials.gov)	June 2023	12/11/2021	A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multip ...	A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Ef ...	Spasticity	Drug: Arbaclofen;Drug: Placebo	RVL Pharmaceuticals, Inc.	NULL	Not yet recruiting	18 Years	65 Years	All	442	Phase 3	NULL
2	NCT04150549 (ClinicalTrials.gov)	June 2023	11/10/2019	FMT for MS Patients	Fecal Microbial Transplantation for Relapsing Multiple Sclerosis Patients - a Placebo-controlled, Do ...	Multiple Sclerosis	Biological: Fecal Microbial Transplants	Lawson Health Research Institute	NULL	Not yet recruiting	18 Years	55 Years	All	34	Phase 2	NULL
3	NCT05658484 (ClinicalTrials.gov)	April 13, 2023	12/12/2022	A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in Ch ...	A Multicenter, Postmarketing Study of Dimethyl Fumarate (Tecfidera; BG00012) in Relapsing Forms of M ...	Multiple Sclerosis	Drug: Dimethyl fumarate	Biogen	NULL	Not yet recruiting	18 Years	65 Years	All	60	Phase 4	NULL
4	NCT05754593 (ClinicalTrials.gov)	April 2023	21/2/2023	Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Gro ...	Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis, Compared to a Control Group	Multiple Sclerosis	Biological: Anti-Mullerian hormone (AMH) level;Other: Antral follicle count (AFC);Other: Clinical as ...	University Hospital, Bordeaux	NULL	Not yet recruiting	25 Years	35 Years	Female	160	N/A	France
5	NCT05740722 (ClinicalTrials.gov)	March 1, 2023	30/1/2023	Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis	Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Tri ...	Multiple Sclerosis;Progressive Multiple Sclerosis	Dietary Supplement: Nicotinamid riboside;Dietary Supplement: Placebo	Haukeland University Hospital	NULL	Not yet recruiting	18 Years	65 Years	All	300	Phase 2	Norway
6	NCT05199688 (ClinicalTrials.gov)	February 28, 2023	3/12/2021	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satral ...	A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Saf ...	Neuromyelitis Optica Spectrum Disorder;NMOSD	Drug: Satralizumab	Hoffmann-La Roche	NULL	Recruiting	2 Years	11 Years	All	8	Phase 3	France;Poland;United Kingdom;Argentina;Italy;Mexico;Ukraine;United States
7	NCT05758831 (ClinicalTrials.gov)	February 28, 2023	17/2/2023	RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.	A Prospective Randomized Trial of Non-inferiority Comparing RItuximab Versus Ocrelizumab in Relapsin ...	Multiple Sclerosis;Relapsing-remitting Multiple Sclerosis	Drug: Perfusion of treatment Rituximab;Drug: Perfusion of treatment Ocrelizumab	Rennes University Hospital	NULL	Not yet recruiting	18 Years	55 Years	All	386	Phase 3	France
8	NCT05208840 (ClinicalTrials.gov)	February 14, 2023	12/1/2022	A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis	Open-Label Multicenter Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation I ...	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche	NULL	Not yet recruiting	18 Years	65 Years	All	50	Phase 4	Russian Federation
9	NCT05701423 (ClinicalTrials.gov)	February 8, 2023	18/1/2023	A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Partici ...	End of Dose Phenomena in Subcutaneous Natalizumab Treated MS Patients	Multiple Sclerosis	Drug: Natalizumab	Biogen	NULL	Recruiting	18 Years	N/A	All	100		Germany
10	NCT03696485 (ClinicalTrials.gov)	February 1, 2023	30/9/2018	Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS	A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and ...	Secondary Progressive Multiple Sclerosis (SPMS)	Biological: SCM -010	Stem Cell Medicine Ltd.	NULL	Not yet recruiting	18 Years	60 Years	All	12	Phase 1/Phase 2	Israel

First Previous1 2 3 4 5…296Next Last